Business Context and Reporting Period
Quoin Pharmaceuticals Ltd. (QNRX), an emerging growth company incorporated in Israel, filed this Form 8-K on April 29, 2024. The report addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the company's listing status.
Key Financial Metrics
This filing is a current report regarding listing compliance and does not contain financial statements. Consequently, data on revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material event reported is the failure of the Company's American Depositary Shares (ADSs) to maintain a minimum closing bid price of $1.00 per ADS for 31 consecutive business days (March 14, 2024, through April 26, 2024). This constitutes a violation of Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-day compliance period, ending October 28, 2024, to regain compliance.
- Remediation Path: Compliance can be achieved if the closing bid price remains at or above $1.00 for a minimum of ten consecutive business days during the compliance period.
- Delisting Risk: If the Company fails to meet the requirement by October 28, 2024, it may be eligible for an additional compliance period only if it meets all other initial listing standards (excluding the bid price) and notifies Nasdaq in writing.
- Management Action: Management intends to actively monitor the bid price and consider available options to regain compliance. The notice has no immediate effect on the trading of ADSs.
Investor Verification Checklist
- Verify the current closing bid price of QNRX ADSs to assess proximity to the $1.00 threshold.
- Monitor the company's stock price for ten consecutive business days to determine if the initial compliance path is viable.
- Review the company's market value of publicly held shares to ensure eligibility for a potential second compliance period if the first is missed.
- Check for future announcements regarding reverse stock splits or other corporate actions intended to address the bid price deficiency.